Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 4/20 | 0.76 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.76 |
| ▸ | ACACB | O00763 | 3/20 | 0.63 |
| ▸ | ACACA | Q13085 | 2/20 | 0.63 |
| ▸ | NPC1 | O15118 | 8/20 | 0.58 |
| ▸ | RAB9A | P51151 | 7/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.58 |
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | LTA4H | P09960 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.51 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.51 |
| ▸ | RELA | Q04206 | 2/20 | 0.51 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL35210439 | 0.94 | S1PR1 (0.67) | S1PR1S1PR3ACACBACACANPC1 | |
| SCHEMBL35210453 | 0.89 | NPC1 (0.64) | S1PR1S1PR3NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL13417242 | 0.86 | S1PR1 (1.00) | S1PR1S1PR3ACACBACACANPC1 | |
| SCHEMBL21153222 | 0.85 | S1PR1 (0.55) | S1PR1S1PR3ACACBACACANPC1 | |
| SCHEMBL19968728 | 0.84 | S1PR1 (0.69) | S1PR1S1PR3ACACBACACANPC1 | |
| SCHEMBL35210441 | 0.83 | S1PR1 (0.53) | S1PR1S1PR3ACACBACACANPC1 | |
| SCHEMBL13926721 | 0.82 | S1PR1 (0.69) | S1PR1S1PR3ACACBACACANPC1 | |
| SCHEMBL3057134 | 0.81 | RAB9A (0.74) | S1PR1NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL7294501 | 0.80 | ACACB (0.69) | S1PR1S1PR3ACACBACACANPC1 | |
| SCHEMBL35210430 | 0.80 | S1PR1 (0.49) | S1PR1S1PR3NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125371-A1 | METHOD FOR INHIBITING CLOSTRIDIOIDES DIFFICILE SPORE GERMINATION | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2026-05-07 | — | — | US | disclosed |
| US-11168062-B2 | Compounds for the treatment of Clostridium difficile infection | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2021-11-09 | — | — | US | disclosed |
| US-20210340116-A1 | COMPOUNDS FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2021-11-04 | — | — | US | disclosed |
| US-20210340117-A1 | COMPOUNDS FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2021-11-04 | — | — | US | disclosed |
| US-20190210984-A1 | COMPOUNDS FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125371-A1 | METHOD FOR INHIBITING CLOSTRIDIOIDES DIFFICILE SPORE GERMINATION | CYP8B1, SPOUT1, O60361 | S1PR1 3111/4885S1PR3 2606/4885ACACB 827/4885 |
| US-20190210984-A1 | COMPOUNDS FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION | VNN1, NGLY1, NUCB2 | S1PR1 3916/4885S1PR3 4424/4885ACACB 2585/4885 |
| US-11168062-B2 | Compounds for the treatment of Clostridium difficile infection | VNN1, NGLY1, NUCB2 | S1PR1 3916/4885S1PR3 4424/4885ACACB 2585/4885 |
| US-20210340117-A1 | COMPOUNDS FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION | VNN1, NGLY1, NUCB2 | S1PR1 3916/4885S1PR3 4424/4885ACACB 2585/4885 |
| US-20210340116-A1 | COMPOUNDS FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION | VNN1, NGLY1, NUCB2 | S1PR1 3916/4885S1PR3 4424/4885ACACB 2585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.